COST-EFFECTIVENESS OF DIMETHYL FUMARATE TREATMENT FOR RELAPSING REMITTING MULTIPLE SCLEROSIS FROM A DANISH PERSPECTIVE

被引：3
|
作者：
Olsen, J. [1 ]
Wiren, A. [2 ]
机构：
[1] HOLTE, Incent Aps, Copenhagen, Denmark
[2] Biogen Denmark AS, Copenhagen, Denmark
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
10.1016/j.jval.2015.09.2469
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PND54
引用
收藏
页码：A758 / A758
页数：1
相关论文
共 50 条
  • [1] Cost-Effectiveness Analysis of Dimethyl Fumarate in the Treatment of Relapsing Remitting Multiple Sclerosis: An Italian Societal Perspective
    Mantovani, Lorenzo Giovanni
    Furneri, Gianluca
    Bitonti, Rossella
    Cortesi, Paolo
    Puma, Elisa
    Santoni, Laura
    Prosperini, Luca
    FARMECONOMIA-HEALTH ECONOMICS AND THERAPEUTIC PATHWAYS, 2019, 20 (01) : 73 - 86
  • [2] COST-EFFECTIVENESS OF CLADRIBINE TABLETS AND DIMETHYL FUMARATE IN THE TREATMENT OF RELAPSING REMITTING MULTIPLE SCLEROSIS IN SPAIN
    Ginestal, R.
    Duran, O.
    Rubio Terres, C.
    Rubio-Rodriguez, D.
    De Los Santos, H.
    Ordonez, C.
    Sanchez, I
    VALUE IN HEALTH, 2022, 25 (12) : S82 - S82
  • [3] Cost-effectiveness of cladribine tablets and dimethyl fumarate in the treatment of relapsing remitting multiple sclerosis in Spain
    Ginestal, Ricardo
    Rubio-Terres, Carlos
    Moran, Olga Duran
    Rubio-Rodriguez, Dario
    De Los Santos, Heidi
    Ordonez, Cristina
    Sanchez-Magro, Isabel
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2023, 12 (02)
  • [4] COST-EFFECTIVENESS ANALYSIS OF DIMETHYL FUMARATE IN THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN ITALY
    Mantovani, L. G.
    Furneri, G.
    Cortesi, P. A.
    Puma, E.
    Santoni, L.
    Prosperini, L.
    VALUE IN HEALTH, 2019, 22 : S740 - S741
  • [5] Cost-Effectiveness of Dimethyl Fumarate Compared to Teriflunomide for Relapsing Remitting Multiple Sclerosis Patients in Italy
    Mantovani, Lorenzo Giovanni
    Cortesi, Paolo Angelo
    Cardillo, Alessandra
    Santoni, Laura
    Prosperini, Luca
    FARMECONOMIA-HEALTH ECONOMICS AND THERAPEUTIC PATHWAYS, 2022, 23 (01) : 13 - 28
  • [6] COST-EFFECTIVENESS ANALYSIS OF DELAYED-RELEASE DIMETHYL FUMARATE FOR THE TREATMENT OF RELAPSING REMITTING MULTIPLE SCLEROSIS IN SPAIN
    Gasche, D.
    Restovic, G.
    Casado, V
    Ramirez-Boix, P.
    Martinez Lopez, J.
    VALUE IN HEALTH, 2015, 18 (07) : A755 - A755
  • [7] The cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis in Canada
    Su, Wenqing
    Kansal, Anuraag
    Vicente, Colin
    Deniz, Baris
    Sarda, Sujata
    JOURNAL OF MEDICAL ECONOMICS, 2016, 19 (07) : 718 - 727
  • [8] COST-EFFECTIVENESS OF DIMETHYL-FUMARATE COMPARED TO TERIFLUNOMIDE FOR RELAPSING REMITTING MULTIPLE SCLEROSIS PATIENTS IN ITALY
    Mantovani, L. G.
    Furneri, G.
    Cortesi, P. A.
    Santoni, L.
    Prosperini, L.
    Cardillo, A.
    VALUE IN HEALTH, 2020, 23 : S630 - S630
  • [9] Cost-effectiveness analysis of delayed-release dimethyl-fumarate in the treatment of relapsing-remitting multiple sclerosis in Italy
    Furneri, Gianluca
    Santoni, Laura
    Marchesi, Chiara
    Iannazzo, Sergio
    Cortesi, Paolo Angelo
    Piacentini, Patrizio
    Caputi, Achille Patrizio
    Mantovani, Lorenzo Giovanni
    FARMECONOMIA-HEALTH ECONOMICS AND THERAPEUTIC PATHWAYS, 2016, 17 (02) : 67 - 80
  • [10] COST-EFFECTIVENESS ANALYSIS OF DELAYED-RELEASE DIMETHYL-FUMARATE IN THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN ITALY
    Fumeri, G.
    Santoni, L.
    Marchesi, C.
    Iannazzo, S.
    Cortesi, R.
    Piacentini, P.
    Caputi, A.
    Mantovani, L. G.
    VALUE IN HEALTH, 2015, 18 (07) : A697 - A697
12345